Jeffrey L. B. Bohnen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jeffrey L. B. Bohnen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Nicolaas I. Bohnen
Department of Radiology, University of Michigan , Ann Arbor, MI 48109
2 shared publications - Stiven Roytman
Department of Radiology, University of Michigan, Ann Arbor, MI 48105-9755, USA
2 shared publications - Travis P. Wigstrom
Department of Chemistry, Michigan Technological University, 1400 Townsend Drive, Houghton, MI 49931, USA
2 shared publications - Alexis Griggs
University of Michigan Department of Radiology, Ann Arbor, Michigan, United States of America
1 shared publication - Alexis M. Griggs
Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA
1 shared publication Claire Martino
College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, 48109, USA
1 shared publication
Latest Publications
- Open Access
- 21 November 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00791
Dietary tributyrin supplementation in Parkinson’s disease: An open-label target engagement study
- 21 November 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00791
Open AccessDietary tributyrin supplementation in Parkinson’s disease: An open-label target engagement study
- Open Access
- 1 April 2024
- Published by Springer Nature in Research Square
Mitochondrial impairment demonstrated via 18F-BCPP-EF mitochondrial complex I PET ligand in case study of individual with bipolar disorder and alcohol use disorder
Background With Bipolar Disorder (BD) having a lifetime prevalence of 4.4% and a significant portion of patients being chronically burdened by symptoms, there has been an increased focus on uncovering new targets for intervention in BD. One area that has shown early promise is the mitochondrial hypothesis, with supporting evidence in the form of mtDNA copy number, SNPs, ETC complex activity in peripheral cells, postmortem analyses of ETC function, and iPSC-derived biomarkers, among others. Despite this compelling evidence, at the time of this publication no studies have utilized PET imaging to assess mitochondrial function in the setting of BD. Case Presentation Our participant is a 58 year old male with a past medical history notable for alcohol use disorder and bipolar disorder (unspecified type) who, while enrolled as a control for a separate trial, underwent PET imaging with the mitochondrial complex 1 PET ligand 18F-BCPP-EF. Those images were compared to normal controls which demonstrated significant overlap between areas of dysfunction identified with the 18F-BCPP-EF PET ligand and areas of dysfunction previously identified in the setting of BD with fMRI techniques. That overlap was seen in both affective and cognitive circuits, with mitochondrial dysfunction in the fronto-limbic, ventral affective, and dorsal cognitive circuits showing particularly significant differences. Conclusions Despite mounting evidence implicating mitochondria in BD, this study represents the first PET imaging study to investigate this mechanistic connection. There were key limitations in the form of comorbid alcohol use disorder, limited statistical power inherent to a case study, no sex matched controls, and the absence of a comprehensive psychiatric history. However, even with these limitations in mind, the significant overlap between areas of dysfunction previously demonstrated on fMRI and this 18F-BCPP-EF PET ligand imaging provides compelling preliminary evidence that strengthens the mechanistic link between mitochondrial dysfunction and Bipolar Disorder and warrants further investigation.
- 1 April 2024
- Published by Springer Nature in Research Square
Open AccessMitochondrial impairment demonstrated via 18F-BCPP-EF mitochondrial complex I PET ligand in case study of individual with bipolar disorder and alcohol use disorder
Background With Bipolar Disorder (BD) having a lifetime prevalence of 4.4% and a significant portion of patients being chronically burdened by symptoms, there has been an increased focus on uncovering new targets for intervention in BD. One area that has shown early promise is the mitochondrial hypothesis, with supporting evidence in the form of mtDNA copy number, SNPs, ETC complex activity in peripheral cells, postmortem analyses of ETC function, and iPSC-derived biomarkers, among others. Despite this compelling evidence, at the time of this publication no studies have utilized PET imaging to assess mitochondrial function in the setting of BD. Case Presentation Our participant is a 58 year old male with a past medical history notable for alcohol use disorder and bipolar disorder (unspecified type) who, while enrolled as a control for a separate trial, underwent PET imaging with the mitochondrial complex 1 PET ligand 18F-BCPP-EF. Those images were compared to normal controls which demonstrated significant overlap between areas of dysfunction identified with the 18F-BCPP-EF PET ligand and areas of dysfunction previously identified in the setting of BD with fMRI techniques. That overlap was seen in both affective and cognitive circuits, with mitochondrial dysfunction in the fronto-limbic, ventral affective, and dorsal cognitive circuits showing particularly significant differences. Conclusions Despite mounting evidence implicating mitochondria in BD, this study represents the first PET imaging study to investigate this mechanistic connection. There were key limitations in the form of comorbid alcohol use disorder, limited statistical power inherent to a case study, no sex matched controls, and the absence of a comprehensive psychiatric history. However, even with these limitations in mind, the significant overlap between areas of dysfunction previously demonstrated on fMRI and this 18F-BCPP-EF PET ligand imaging provides compelling preliminary evidence that strengthens the mechanistic link between mitochondrial dysfunction and Bipolar Disorder and warrants further investigation.
- Open Access
Ketogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical Trial
There is growing interest in the investigation of ketogenic diets as a potential therapy for bipolar disorder. The overlapping pharmacotherapies utilized for both bipolar disorder and seizures suggest that a mechanistic overlap may exist between these conditions, with fasting and the ketogenic diet representing the most time-proven therapies for seizure control. Recently, preliminary evidence has begun to emerge supporting a potential role for ketogenic diets in treating bipolar disorder. Notably, some patients may struggle to initiate a strict diet in the midst of a mood episode or significant life stressors. The key question addressed by this pilot clinical trial protocol is if benefits can be achieved with a less restrictive diet, as this would allow such an intervention to be accessible for more patients. Recent development of so-called ketone esters, that once ingested is converted to natural ketone bodies, combined with low glycemic index dietary changes has the potential to mimic two foundational components of therapeutic ketosis: high levels of ketones and minimal spiking of glucose/insulin. This pilot clinical trial protocol thus aims to investigate the effect of a ‘ketogenic-mimicking diet’ (combining supplementation of ketone esters with a low glycemic index dietary intervention) on neural network stability, mood, and biomarker outcomes in the setting of bipolar disorder. Positive findings obtained via this pilot clinical trial protocol may support future target engagement studies of ketogenic-mimicking diets or related ketogenic interventions. A lack of positive findings, in contrast, may justify a focus on more strict dietary interventions for future research.
Open AccessKetogenic-Mimicking Diet as a Therapeutic Modality for Bipolar Disorder: Biomechanistic Rationale and Protocol for a Pilot Clinical Trial
There is growing interest in the investigation of ketogenic diets as a potential therapy for bipolar disorder. The overlapping pharmacotherapies utilized for both bipolar disorder and seizures suggest that a mechanistic overlap may exist between these conditions, with fasting and the ketogenic diet representing the most time-proven therapies for seizure control. Recently, preliminary evidence has begun to emerge supporting a potential role for ketogenic diets in treating bipolar disorder. Notably, some patients may struggle to initiate a strict diet in the midst of a mood episode or significant life stressors. The key question addressed by this pilot clinical trial protocol is if benefits can be achieved with a less restrictive diet, as this would allow such an intervention to be accessible for more patients. Recent development of so-called ketone esters, that once ingested is converted to natural ketone bodies, combined with low glycemic index dietary changes has the potential to mimic two foundational components of therapeutic ketosis: high levels of ketones and minimal spiking of glucose/insulin. This pilot clinical trial protocol thus aims to investigate the effect of a ‘ketogenic-mimicking diet’ (combining supplementation of ketone esters with a low glycemic index dietary intervention) on neural network stability, mood, and biomarker outcomes in the setting of bipolar disorder. Positive findings obtained via this pilot clinical trial protocol may support future target engagement studies of ketogenic-mimicking diets or related ketogenic interventions. A lack of positive findings, in contrast, may justify a focus on more strict dietary interventions for future research.